Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Looming GMPs Could Doom Some Firms Unless Industry, FDA Lend Support

This article was originally published in The Tan Sheet

Executive Summary

Some smaller dietary supplement firms could need support from the industry and flexibility from FDA to pay for complying with good manufacturing practices and still keep their doors open

You may also be interested in...



Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

As Supplement GMP Implementation Hits Zero Hour, Small Firms Still Struggle

FDA's final rule for dietary supplement good manufacturing practices completed its phase-in for the industry June 25, and the agency now prepares to conduct inspections of small firms, which have struggled the most to comply with the regulation

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel